Skip to search formSkip to main contentSkip to account menu

recombinant antihemophilic factor VIII

Known as: recombinant factor viii, rfviii 
National Institutes of Health

Related topics

Related topics

9 relations

Narrower (6)

Antihemophilic Factor, Human RecombinantHumate-PKogenateOctocog alfa
Antihemophilic Factor, Human Recombinant 1 UNT InjectionAntihemophilic Factor, Human Recombinant 1 UNT Injection [Recombinate]

Broader (1)

Factor VIII

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Adsorption and function of recombinant factor VIII at solid-water interfaces in the presence of Tween-80.
The adsorption, structural alteration and biological activity of a recombinant Factor VIII was investigated in the presence of… 
2007
2007
Defining ‘full‐length’ recombinant factor VIII: a comparative structural analysis
Summary.  Coagulation factor VIII (FVIII) is an important glycoprotein co‐factor involved in haemostasis, functioning to… 
Review
2006
Review
2006
Recombinant vs. plasma‐derived products, especially those with intact VWF, regarding inhibitor development
Summary.  The development of inhibitors in previously untreated patients (PUPs) with haemophilia A is correlated with a variety… 
Review
2004
Review
2004
New high‐technology products for the treatment of haemophilia
Summary.  This review will focus on new technologies in development that promise to lead to further advances in haemophilia… 
2004
2004
Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate®): a prospective pharmacovigilance study
Summary.  Clinical trials to date have not been adequately powered to assess comparatively infrequent events such as inhibitor… 
2001
2001
Potency estimation of recombinant factor VIII: effect of assay method and standard
Large potency discrepancies between the chromogenic and one‐stage clotting methods have been reported for patients' plasma… 
Highly Cited
1998
Highly Cited
1998
A prospective clinical trial of implantable central venous access in children with haemophilia
To assess the risks associated with the use of central venous ports in children with haemophilia, 15 HIV‐negative patients were… 
Highly Cited
1997
Highly Cited
1997
A Multicenter Pharmacosurveillance Study for the Evaluation of the Efficacy and Safety of Recombinant Factor VIII in the Treatment of Patients with Hemophilia A
Summary In this open multicenter study the safety and efficacy of recombinant factor VIII (rFVIII) was assessed in 39 previously… 
1990
1990
Characterization of recombinant factor VIII and a recombinant factor VIII deletion mutant using a rabbit immunogenicity model system.
The use of factor VIII prepared genetically engineered cell lines (rFVIII) may avoid some of the problems inherently associated… 
Highly Cited
1987
Highly Cited
1987
Characterization of recombinant human factor VIII.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)